Last updated: 03/11/2026 12:20:22
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
GSK study ID
220929
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Trial status
Terminated (halted prematurely)
Terminated (halted prematurely)
Trial overview
Official title: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Trial description: Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Absolute Change from Baseline in Forced Vital Capacity (FVC) (milliliters [mL]) at Week 26
Timeframe: Baseline and at Week 26
Secondary outcomes:
Absolute Change from Baseline in Forced Vital Capacity (mL) at Weeks 4, 8, 12 and 18
Timeframe: Baseline and at Week 4, Week 8, Week 12 and Week 18
Absolute Change from Baseline in Percent Predicted Forced Vital Capacity (%) at Weeks 4, 8, 12, 18 and 26
Timeframe: Baseline and at Week 4, Week 8, Week 12, Week 18 and Week 26
Number of Participants Achieving Relative Decline from Baseline in FVC (mL) Less than or Equal to (≤) 5 Percent (%) at Week 26
Timeframe: Baseline and at Week 26
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: Up to Week 26
Number of Participants with Clinically Important Findings in Vital Signs
Timeframe: Baseline and up to Week 26
Number of Participants with Clinically Important Findings in Electrocardiogram (ECG)
Timeframe: Baseline and up to Week 26
Number of Participants with Clinically Important Findings in Hematology
Timeframe: Baseline and up to Week 26
Number of Participants with Clinically Important Findings in Hepatobiliary Parameters
Timeframe: Baseline and up to Week 26
Number of Participants with Clinically Important Findings in Clinical Chemistry
Timeframe: Baseline up to Week 26
Maximum observed concentration (Cmax) of GSK3915393 in IPF Participants
Timeframe: At Week 2 (pre-dose, and 0.5, 1, 1.5, 2, 3 and 4 hour post-dose)
Area under the time-concentration curve (AUC) from Zero (pre-dose) to 4 hours post-dose sample (AUC0-4 hour) of GSK3915393
Timeframe: At Week 2 (pre-dose, and 0.5, 1, 1.5, 2, 3 and 4 hour post-dose)
Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC-inf) of GSK3915393
Timeframe: At Week 2 (pre-dose, and 0.5, 1, 1.5, 2, 3 and 4 hour post-dose)
Interventions:
Drug: GSK3915393
Drug: Placebo
Enrollment:
158
Observational study model:
Not applicable
Primary completion date:
2025-01-10
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Idiopathic Pulmonary Fibrosis
Product
Not applicable
Collaborators
Not applicable
Study date(s)
April 2024 to October 2025
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Participants with IPF diagnosed within 5 years prior to screening based on the applicable American Thoracic Society (ATS)/ European Respiratory Society (ERS)/ Japanese Respiratory Society (JRS)/ Latin American Thoracic Society (ALAT) Guideline at the time of diagnosis.
- Centrally read chest High Resolution Computed Tomography (HRCT) obtained at screening or historical HRCT obtained within 12 months of screening that is consistent with Usual interstitial pneumonia (UIP) or probable UIP (if indeterminate HRCT finding, IPF may be confirmed locally by historical biopsy).
- Participants with Interstitial Lung Disease (ILD) associated with other known causes.
- Diagnosis of sarcoidosis or any systemic autoimmune disease (including but not limited to scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus and rheumatoid arthritis).
Inclusion and exclusion criteria
Inclusion criteria:
- Participants with IPF diagnosed within 5 years prior to screening based on the applicable American Thoracic Society (ATS)/ European Respiratory Society (ERS)/ Japanese Respiratory Society (JRS)/ Latin American Thoracic Society (ALAT) Guideline at the time of diagnosis.
- Centrally read chest High Resolution Computed Tomography (HRCT) obtained at screening or historical HRCT obtained within 12 months of screening that is consistent with Usual interstitial pneumonia (UIP) or probable UIP (if indeterminate HRCT finding, IPF may be confirmed locally by historical biopsy).
- FVC greater than or equal to (>=) 45 percent (%) of predicted normal.
- Diffusing Capacity (of Lung) for Carbon Monoxide (DLCO) >=25% of predicted normal corrected for hemoglobin (Hb).
- Prebronchodilator Forced Expiratory Volume in 1 second (FEV1)/FVC >=0.7.
- If receiving antifibrotics must be on stable dose of nintedanib or pirfenidone for at least 12 weeks prior to screening.
- If not receiving approved antifibrotics (pirfenidone or nintedanib) there should be a valid reason for this, such as previous failure, contraindications, failure to meet national or regional eligibility criteria for anti-fibrotic treatment, or participant choice.
- If not currently receiving pirfenidone or nintedanib, participant must have stopped pirfenidone or nintedanib for at least 4 weeks prior to screening.
- Body weight >=40 kilogram (kg) and body mass index within the range 18.5-35 kilogram per meter square (kg/m^2) (inclusive).
- A female participant is eligible to participate if a woman of nonchildbearing potential (WONCBP)
- Capable of giving signed informed consent
Exclusion criteria:
- Participants with Interstitial Lung Disease (ILD) associated with other known causes.
- Diagnosis of sarcoidosis or any systemic autoimmune disease (including but not limited to scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus and rheumatoid arthritis).
- Acute IPF exacerbation within 6 months prior to screening and/or during the screening period (investigator-determined).
- Clinically significant non-parenchymal lung disease (e.g., asthma, chronic obstructive pulmonary disease, cavitary or pleural diseases) at screening.
- Diagnosis of severe pulmonary hypertension (investigator-determined)
- Extent of emphysema is greater than the extent of fibrosis according to reported results from the most recent HRCT.
- History of previous lung transplant or recent major surgery (investigator-determined) within 12 weeks prior to screening or planned during the trial period. Registration on a transplant waiting list is allowed.
- Clinically significant respiratory tract infection (e.g., active tuberculosis, infectious pneumonia, Corona virus disease 2019 [COVID-19]) requiring treatment within 4 weeks prior to and/or during the screening period.
- Cigarette smoking (including e-cigarettes) either current or within 3 months before screening.
- Current or chronic liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones).
- Alanine transaminase (ALT), Aspartate transaminase (AST), Alkaline phosphatase (ALP) greater than (>) 2x Upper Limit of Normal (ULN) and bilirubin >1.5x ULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than (<) 35% at screening).
- Clinically significant abnormalities detected on ECG of either rhythm or conduction, a Corrected QT interval (QTc) >450 millisecond (msec) or QTc > 480msec for participants with a bundle branch block and/or a pacemaker who are actively ventricularly pacing during the screening ECG.
- Participants with pacemakers who are not pacing at the time of the screening ECG should have a non-paced QTc <450 msec. Prior/Concomitant Therapy-
- Simultaneous use of pirfenidone and nintedanib at screening.
- Received systemic corticosteroids equivalent to prednisone >10 milligrams/day or equivalent within 2 weeks of screening period.
- Use of any of the following therapies within 4 weeks prior to screening and during the screening period or planned during the study:
- Immunomodulatory therapies, including but not limited to azathioprine, mycophenolate mofetil, methotrexate, tacrolimus, cyclophosphamide, imatinib, Tumour Necrosis Factor -Alpha (TNF- α) inhibitors.
- Medications that are under investigation for the treatment of IPF including inhaled treprostinil and Phosphodiesterase-4 (PDE-4) inhibitors. Symptomatic cough therapies are allowed.
- Current use of systemic strong and moderate inducers or inhibitors of Cytochrome P450 3A4 (CYP3A4) that cannot be safely discontinued or switched to an alternative agent at least 14 days before randomization.
- Current use of systemic CYP3A4 substrates that have a narrow therapeutic index that cannot be safely discontinued or switched to an alternative agent at least 14 days before randomization.
Trial location(s)
Location
GSK Investigational Site
Santiago de Compostela, Spain, 15706
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ciudad Autonoma de Bueno, Argentina, C1207AAP
Status
Study Complete
Location
GSK Investigational Site
Leeds West Yorkshire, Unmapped, LS9 7TF
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, CA, Unmapped, 90033
Status
Terminated/Withdrawn
Study documents
No study documents available.
Results overview
Study Results yet to be posted
Recruitment status
Terminated (halted prematurely)
Actual primary completion date
2025-01-10
Actual study completion date
2025-01-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website